JP2022529929A5 - - Google Patents

Info

Publication number
JP2022529929A5
JP2022529929A5 JP2021561599A JP2021561599A JP2022529929A5 JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5 JP 2021561599 A JP2021561599 A JP 2021561599A JP 2021561599 A JP2021561599 A JP 2021561599A JP 2022529929 A5 JP2022529929 A5 JP 2022529929A5
Authority
JP
Japan
Prior art keywords
antibody
humanized anti
seq
patient
domain described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529929A (ja
JP7778567B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028861 external-priority patent/WO2020215019A1/en
Publication of JP2022529929A publication Critical patent/JP2022529929A/ja
Publication of JP2022529929A5 publication Critical patent/JP2022529929A5/ja
Priority to JP2025122188A priority Critical patent/JP2025169256A/ja
Application granted granted Critical
Publication of JP7778567B2 publication Critical patent/JP7778567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561599A 2019-04-17 2020-04-17 α4β7阻害薬及びIL-23阻害薬の併用療法 Active JP7778567B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122188A JP2025169256A (ja) 2019-04-17 2025-07-22 α4β7阻害薬及びIL-23阻害薬の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835349P 2019-04-17 2019-04-17
US62/835,349 2019-04-17
PCT/US2020/028861 WO2020215019A1 (en) 2019-04-17 2020-04-17 Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122188A Division JP2025169256A (ja) 2019-04-17 2025-07-22 α4β7阻害薬及びIL-23阻害薬の併用療法

Publications (3)

Publication Number Publication Date
JP2022529929A JP2022529929A (ja) 2022-06-27
JP2022529929A5 true JP2022529929A5 (cg-RX-API-DMAC7.html) 2023-04-25
JP7778567B2 JP7778567B2 (ja) 2025-12-02

Family

ID=72837950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561599A Active JP7778567B2 (ja) 2019-04-17 2020-04-17 α4β7阻害薬及びIL-23阻害薬の併用療法
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α4β7阻害薬及びIL-23阻害薬の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122188A Pending JP2025169256A (ja) 2019-04-17 2025-07-22 α4β7阻害薬及びIL-23阻害薬の併用療法

Country Status (5)

Country Link
US (1) US20230096620A1 (cg-RX-API-DMAC7.html)
EP (1) EP3956358A4 (cg-RX-API-DMAC7.html)
JP (2) JP7778567B2 (cg-RX-API-DMAC7.html)
MA (1) MA55735A (cg-RX-API-DMAC7.html)
WO (1) WO2020215019A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240103043A (ko) * 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2026058045A1 (en) * 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3277719B1 (en) * 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2018003376A (es) * 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
WO2017106595A1 (en) * 2015-12-18 2017-06-22 Sciadonics, Inc. Lipid formulations containing bioactive fatty acids and a non-fatty acid anti-inflammatory agent
JP7162533B2 (ja) * 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ, インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
CN116712540A (zh) * 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
EP3601350A1 (en) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
IL270201B2 (en) * 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
EP3810085A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7119114B2 (ja) 潰瘍性大腸炎を治療する方法
CN112689512B (zh) 用于治疗银屑病的组合物和方法
JP2022188083A (ja) 化膿性汗腺炎の処置
WO2022075476A1 (en) Method for treating ox40 related disease
JP2024069230A5 (cg-RX-API-DMAC7.html)
JP2022523530A (ja) 化膿性汗腺炎の治療のための抗IL-α抗体
JP2023522196A (ja) 化膿性汗腺炎の治療
JP2022529266A (ja) 乾癬性関節炎に罹患している対象者の治療方法
JP7093940B2 (ja) 全身性強皮症治療用医薬組成物
JP7297930B2 (ja) クローン病を治療する方法に使用するためのミリキズマブ
CN120204387A (zh) 治疗银屑病的方法
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
JP7863690B2 (ja) 潰瘍性大腸炎を治療する方法
JP2020517648A5 (cg-RX-API-DMAC7.html)
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
WO2024077113A1 (en) Methods of treating fatigue in ulcerative colitis
WO2026060205A1 (en) PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
JP2024516019A (ja) 抗baffr抗体を使用する全身性エリテマトーデスのための治療
WO2025257781A1 (en) Treatment of systemic sclerosis using anti-baff-r antibodies
HK40052952B (en) Compositions and methods for treatment of psoriasis
HK40052952A (en) Compositions and methods for treatment of psoriasis
Swendrowski Ustekinumab: a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases
CN116829582A (zh) 安全施用抗Tau抗体的方法